Login to Your Account

Armo Enters Clinical Trials with ‘Killer’ Cancer Compound

By Catherine Shaffer
Staff Writer

Monday, November 25, 2013
Armo Biosciences Inc. began testing its pegylated recombinant human interleukin-10 (IL-10) compound, AM0010, in the first cohort of patients in a Phase I trial in patients with advanced solid tumors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription